{"protocolSection": {"identificationModule": {"nctId": "NCT00627445", "orgStudyIdInfo": {"id": "BIASP-1858"}, "organization": {"fullName": "Novo Nordisk A/S", "class": "INDUSTRY"}, "briefTitle": "Effect of Biphasic Insulin Aspart 50 on Blood Glucose Control in Subjects With Type 2 Diabetes", "officialTitle": "Effect of Biphasic Insulin Aspart 50 Compared to Biphasic Insulin Aspart 30 Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes"}, "statusModule": {"statusVerifiedDate": "2014-10", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-02"}, "primaryCompletionDateStruct": {"date": "2009-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-02-22", "studyFirstSubmitQcDate": "2008-02-29", "studyFirstPostDateStruct": {"date": "2008-03-03", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-03-11", "resultsFirstSubmitQcDate": "2010-03-11", "resultsFirstPostDateStruct": {"date": "2010-03-31", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2014-10-14", "lastUpdatePostDateStruct": {"date": "2014-10-22", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novo Nordisk A/S", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This trial is conducted in Asia. The trial aims to investigate if the blood glucose control of biphasic insulin aspart 50 is at least as effective as treatment with biphasic insulin aspart 30 both in combination with metformin."}, "conditionsModule": {"conditions": ["Diabetes", "Diabetes Mellitus, Type 2"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 441, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "BIAsp 50-50-30", "type": "EXPERIMENTAL", "description": "Biphasic insulin aspart 50 administered before breakfast and lunch + biphasic insulin aspart 30 at dinner combined with metformin", "interventionNames": ["Drug: biphasic insulin aspart 30", "Drug: metformin", "Drug: biphasic insulin aspart 50"]}, {"label": "BIAsp 30-30", "type": "ACTIVE_COMPARATOR", "description": "Biphasic insulin aspart 30 administered before breakfast and dinner combined with metformin", "interventionNames": ["Drug: biphasic insulin aspart 30", "Drug: metformin"]}], "interventions": [{"type": "DRUG", "name": "biphasic insulin aspart 30", "description": "Treat-to-target dose titration scheme (dose adjusted individually), s.c. (under the skin) injection before dinner", "armGroupLabels": ["BIAsp 30-30", "BIAsp 50-50-30"]}, {"type": "DRUG", "name": "metformin", "description": "Tablets, 500 - 2000 mg, once, twice or three times daily", "armGroupLabels": ["BIAsp 30-30", "BIAsp 50-50-30"]}, {"type": "DRUG", "name": "biphasic insulin aspart 50", "description": "Treat-to-target dose titration scheme (dose adjusted individually), s.c. (under the skin) injection before breakfast and lunch", "armGroupLabels": ["BIAsp 50-50-30"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Glycosylated Haemoglobin A1c (HbA1c)", "description": "Change in glycosylated haemoglobin A1c (HbA1c) from week 0 (baseline) to end of treatment (week 16)", "timeFrame": "week 0, week 16"}], "secondaryOutcomes": [{"measure": "The Percentage of Subjects Achieving HbA1c Treatment Targets", "description": "The percentage of subjects who after 16 weeks of treatment met the glycosylated haemoglobin A1c (HbA1c) treatment targets below 7%, or below or equal to 6.5%.", "timeFrame": "week 16"}, {"measure": "Change and Daily Average in 8-point Plasma Glucose", "description": "Change in 8-point plasma glucose from baseline (week 0) to at end of treatment (week 16). 8-point plasma glucose was measured at following time points: Before each meal, 120 minutes after the start of each meal, at bedtime, and at 3:00 AM in the morning. Daily average was calculated at the end of treatment.", "timeFrame": "week 0, week 16"}, {"measure": "Change and Daily Average in Prandial Plasma Glucose Increment", "description": "Change in prandial (mealtime) plasma glucose increment from baseline (week 0) to end of treatment (week 16). Daily average prandial plasma glucose increment was calculated at end of treatment.", "timeFrame": "week 0, week 16"}, {"measure": "The Total Increase in Total Daily Insulin Dose Per Body Weight", "description": "The total increase in total daily insulin dose per body weight from baseline (week 0) to end of treatment (week 16).", "timeFrame": "week 0, week 16"}, {"measure": "Change in Body Weight", "description": "Change in body weight from baseline (week 0) to end of treatment (week 16)", "timeFrame": "week 0, week 16"}, {"measure": "Number of Hypoglycaemic Episodes", "description": "Number of hypoglycaemic episodes occurring after baseline (week 0) to the end of treatment (week 16) in each treatment group. Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 3.1 mmol/L or 56 mg/dL. Symptoms only if subject was able to treat her/himself and with either no plasma glucose or blood glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L or 56 mg/dL.", "timeFrame": "weeks 0-16"}, {"measure": "Number of Nocturnal Hypoglycaemic Episodes", "description": "Number of nocturnal hypoglycaemic episodes occurring after baseline (week 0) to end of treatment (week 16) in each treatment group. Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 3.1 mmol/L or 56 mg/dL. Symptoms only if subject was able to treat her/himself and with either no plasma glucose or blood glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L or 56 mg/dL.", "timeFrame": "weeks 0-16"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Type 2 diabetes\n* Currently treated with premix human insulin twice daily with or without oral antidiabetic drugs for at least 3 months\n* HbA1c (Glycosylated Haemoglobin A1c) between 7.5% - 12.0% (both inclusive)\n* FPG (Fasting Plasma Glucose) higher than 7.0 mmol/L\n* BMI (Body Mass Index) 23-40 kg/sq.m (both inclusive)\n\nExclusion Criteria:\n\n* Metformin contraindications according to local practice\n* Systemic use of TZDs (thiazolidinediones) for more than 1 month within 6 months prior to this trial", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Global Clinical Registry (GCR, 1452)", "affiliation": "Novo Nordisk A/S", "role": "STUDY_DIRECTOR"}], "locations": [{"city": "Beijing", "state": "Beijing", "zip": "100034", "country": "China", "geoPoint": {"lat": 39.9075, "lon": 116.39723}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "Clinical Trials at Novo Nordisk", "url": "http://novonordisk-trials.com"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Eligible subjects were subjects with type 2 diabetes having an HbA1c (Glycosylated Haemoglobin A1c) between 7.5-12.0 %, and treated with premix human insulin twice daily with or without oral anti-diabetic drugs (OADs) for at least 3 months qualifying for an intensified insulin treatment.", "recruitmentDetails": "15 sites in China", "groups": [{"id": "FG000", "title": "BIAsp 50-50-30", "description": "Individual adjusted dose of biphasic insulin aspart 50 administered before breakfast and lunch and individual adjusted dose of biphasic insulin aspart 30 at dinner in combination with metformin 500-2000 mg, up to three times daily"}, {"id": "FG001", "title": "BIAsp 30-30", "description": "Individual adjusted dose of biphasic insulin aspart 30 administered before breakfast and dinner in combination with metformin 500-2000 mg, up to three times daily"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "219"}, {"groupId": "FG001", "numSubjects": "222"}]}, {"type": "Exposed to Study Drug", "achievements": [{"groupId": "FG000", "numSubjects": "219"}, {"groupId": "FG001", "numSubjects": "222"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "210"}, {"groupId": "FG001", "numSubjects": "210"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "12"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Other", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "8"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "BIAsp 50-50-30", "description": "Individual adjusted dose of biphasic insulin aspart 50 administered before breakfast and lunch and individual adjusted dose of biphasic insulin aspart 30 at dinner in combination with metformin 500-2000 mg, up to three times daily"}, {"id": "BG001", "title": "BIAsp 30-30", "description": "Individual adjusted dose of biphasic insulin aspart 30 administered before breakfast and dinner in combination with metformin 500-2000 mg, up to three times daily"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "219"}, {"groupId": "BG001", "value": "222"}, {"groupId": "BG002", "value": "441"}]}], "measures": [{"title": "Age, Continuous", "description": "Age at screening", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "55.5", "spread": "8.6"}, {"groupId": "BG001", "value": "55.5", "spread": "8.6"}, {"groupId": "BG002", "value": "55.5", "spread": "8.6"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "131"}, {"groupId": "BG001", "value": "113"}, {"groupId": "BG002", "value": "244"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "88"}, {"groupId": "BG001", "value": "109"}, {"groupId": "BG002", "value": "197"}]}]}]}, {"title": "BMI", "description": "BMI = Body Mass Index at randomisation", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "26.06", "spread": "2.70"}, {"groupId": "BG001", "value": "26.27", "spread": "2.73"}, {"groupId": "BG002", "value": "26.17", "spread": "2.71"}]}]}]}, {"title": "Height", "description": "Height at screening", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "cm", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "162.8", "spread": "7.9"}, {"groupId": "BG001", "value": "163.7", "spread": "8.4"}, {"groupId": "BG002", "value": "163.2", "spread": "8.1"}]}]}]}, {"title": "Weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "69.2", "spread": "9.8"}, {"groupId": "BG001", "value": "70.5", "spread": "9.7"}, {"groupId": "BG002", "value": "69.9", "spread": "9.7"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Glycosylated Haemoglobin A1c (HbA1c)", "description": "Change in glycosylated haemoglobin A1c (HbA1c) from week 0 (baseline) to end of treatment (week 16)", "populationDescription": "Intention-to-Treat analysis set (ITT) using LOCF (Last Observation Carried Forward) is all randomised subjects exposed to at least one dose of trial product.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage (%) of total haemoglobin", "timeFrame": "week 0, week 16", "groups": [{"id": "OG000", "title": "BIAsp 50-50-30", "description": "Individual adjusted dose of biphasic insulin aspart 50 administered before breakfast and lunch and individual adjusted dose of biphasic insulin aspart 30 at dinner in combination with metformin 500-2000 mg, up to three times daily"}, {"id": "OG001", "title": "BIAsp 30-30", "description": "Individual adjusted dose of biphasic insulin aspart 30 administered before breakfast and dinner in combination with metformin 500-2000 mg, up to three times daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "216"}, {"groupId": "OG001", "value": "221"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.790", "spread": "0.057"}, {"groupId": "OG001", "value": "-1.517", "spread": "0.056"}]}]}]}, {"type": "SECONDARY", "title": "The Percentage of Subjects Achieving HbA1c Treatment Targets", "description": "The percentage of subjects who after 16 weeks of treatment met the glycosylated haemoglobin A1c (HbA1c) treatment targets below 7%, or below or equal to 6.5%.", "populationDescription": "Intention-to-Treat analysis set (ITT) using LOCF (Last Observation Carried Forward) is all randomised subjects exposed to at least one dose of trial product.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage (%) of subjects", "timeFrame": "week 16", "groups": [{"id": "OG000", "title": "BIAsp 50-50-30", "description": "Individual adjusted dose of biphasic insulin aspart 50 administered before breakfast and lunch and individual adjusted dose of biphasic insulin aspart 30 at dinner in combination with metformin 500-2000 mg, up to three times daily"}, {"id": "OG001", "title": "BIAsp 30-30", "description": "Individual adjusted dose of biphasic insulin aspart 30 administered before breakfast and dinner in combination with metformin 500-2000 mg, up to three times daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "219"}, {"groupId": "OG001", "value": "222"}]}], "classes": [{"title": "Achieving HbA1c <7.0%", "categories": [{"measurements": [{"groupId": "OG000", "value": "65"}, {"groupId": "OG001", "value": "52"}]}]}, {"title": "Achieving HbA1c <=6.5%", "categories": [{"measurements": [{"groupId": "OG000", "value": "47"}, {"groupId": "OG001", "value": "29"}]}]}]}, {"type": "SECONDARY", "title": "Change and Daily Average in 8-point Plasma Glucose", "description": "Change in 8-point plasma glucose from baseline (week 0) to at end of treatment (week 16). 8-point plasma glucose was measured at following time points: Before each meal, 120 minutes after the start of each meal, at bedtime, and at 3:00 AM in the morning. Daily average was calculated at the end of treatment.", "populationDescription": "Intention-to-Treat analysis set (ITT) using LOCF (Last Observation Carried Forward) is all randomised subjects exposed to at least one dose of trial product.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "week 0, week 16", "groups": [{"id": "OG000", "title": "BIAsp 50-50-30", "description": "Individually adjusted dose of biphasic insulin aspart 50 administered before breakfast and lunch in combination with metformin (500-2000 mg up to three times daily)"}, {"id": "OG001", "title": "BIAsp 30-30", "description": "Individually adjusted dose of biphasic insulin aspart 30 at dinner in combination with metformin (500-2000 mg up to three times daily)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "219"}, {"groupId": "OG001", "value": "222"}]}], "classes": [{"title": "Before Breakfast, N= 213, 213", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.52", "spread": "0.10", "lowerLimit": "-0.36", "upperLimit": "0.18"}, {"groupId": "OG001", "value": "-2.43", "spread": "0.10"}]}]}, {"title": "2 hours After Breakfast, N= 213, 210", "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.92", "spread": "0.17", "lowerLimit": "-0.38", "upperLimit": "0.55"}, {"groupId": "OG001", "value": "-4.00", "spread": "0.17"}]}]}, {"title": "Before Lunch, N= 213, 210", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.80", "spread": "0.13", "lowerLimit": "-0.45", "upperLimit": "0.27"}, {"groupId": "OG001", "value": "-2.71", "spread": "0.13"}]}]}, {"title": "2 hours After Lunch, N= 213, 211", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.37", "spread": "0.19", "lowerLimit": "-1.72", "upperLimit": "-0.72"}, {"groupId": "OG001", "value": "-3.15", "spread": "0.18"}]}]}, {"title": "Before Dinner, N= 212, 212", "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.83", "spread": "0.16", "lowerLimit": "-1.41", "upperLimit": "-0.58"}, {"groupId": "OG001", "value": "-2.83", "spread": "0.15"}]}]}, {"title": "2 hours After Dinner, N= 211, 209", "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.46", "spread": "0.18", "lowerLimit": "-0.58", "upperLimit": "0.41"}, {"groupId": "OG001", "value": "-3.37", "spread": "0.18"}]}]}, {"title": "Bedtime, N= 207, 207", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.93", "spread": "0.15", "lowerLimit": "-0.24", "upperLimit": "0.55"}, {"groupId": "OG001", "value": "-3.09", "spread": "0.15"}]}]}, {"title": "3:00 AM, N= 211, 210", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.99", "spread": "0.13", "lowerLimit": "-0.44", "upperLimit": "0.24"}, {"groupId": "OG001", "value": "-1.89", "spread": "0.13"}]}]}, {"title": "Average, N= 213, 212", "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.23", "spread": "0.10", "lowerLimit": "-0.55", "upperLimit": "-0.03"}, {"groupId": "OG001", "value": "-2.94", "spread": "0.10"}]}]}]}, {"type": "SECONDARY", "title": "Change and Daily Average in Prandial Plasma Glucose Increment", "description": "Change in prandial (mealtime) plasma glucose increment from baseline (week 0) to end of treatment (week 16). Daily average prandial plasma glucose increment was calculated at end of treatment.", "populationDescription": "Intention-to-Treat analysis set (ITT) using LOCF (Last Observation Carried Forward) is all randomised subjects exposed to at least one dose of trial product.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "week 0, week 16", "groups": [{"id": "OG000", "title": "BIAsp 50-50-30", "description": "Individual adjusted dose of biphasic insulin aspart 50 administered before breakfast and lunch and individual adjusted dose of biphasic insulin aspart 30 at dinner in combination with metformin 500-2000 mg, up to three times daily"}, {"id": "OG001", "title": "BIAsp 30-30", "description": "Individual adjusted dose of biphasic insulin aspart 30 administered before breakfast and dinner in combination with metformin 500-2000 mg, up to three times daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "219"}, {"groupId": "OG001", "value": "222"}]}], "classes": [{"title": "At Breakfast, N= 213, 210", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.41", "spread": "0.16"}, {"groupId": "OG001", "value": "-1.58", "spread": "0.16"}]}]}, {"title": "At Lunch, N= 213, 210", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.57", "spread": "0.19"}, {"groupId": "OG001", "value": "-0.44", "spread": "0.19"}]}]}, {"title": "At Dinner, N= 210, 209", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.40", "spread": "0.18"}, {"groupId": "OG001", "value": "-0.53", "spread": "0.18"}]}]}, {"title": "Average, N= 213, 211", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.88", "spread": "0.11"}, {"groupId": "OG001", "value": "-0.84", "spread": "0.11"}]}]}]}, {"type": "SECONDARY", "title": "The Total Increase in Total Daily Insulin Dose Per Body Weight", "description": "The total increase in total daily insulin dose per body weight from baseline (week 0) to end of treatment (week 16).", "populationDescription": "Intention-to-Treat analysis set (ITT) is all randomised subjects exposed to at least one dose of trial product.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "U/kg", "timeFrame": "week 0, week 16", "groups": [{"id": "OG000", "title": "BIAsp 50-50-30", "description": "Individual adjusted dose of biphasic insulin aspart 50 administered before breakfast and lunch and individual adjusted dose of biphasic insulin aspart 30 at dinner in combination with metformin 500-2000 mg, up to three times daily"}, {"id": "OG001", "title": "BIAsp 30-30", "description": "Individual adjusted dose of biphasic insulin aspart 30 administered before breakfast and dinner in combination with metformin 500-2000 mg, up to three times daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "210"}, {"groupId": "OG001", "value": "210"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.963", "spread": "0.016"}, {"groupId": "OG001", "value": "0.820", "spread": "0.015"}]}]}]}, {"type": "SECONDARY", "title": "Change in Body Weight", "description": "Change in body weight from baseline (week 0) to end of treatment (week 16)", "populationDescription": "Intention-to-Treat analysis set (ITT) is all randomised subjects exposed to at least one dose of trial product.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "kg", "timeFrame": "week 0, week 16", "groups": [{"id": "OG000", "title": "BIAsp 50-50-30", "description": "Individual adjusted dose of biphasic insulin aspart 50 administered before breakfast and lunch and individual adjusted dose of biphasic insulin aspart 30 at dinner in combination with metformin 500-2000 mg, up to three times daily"}, {"id": "OG001", "title": "BIAsp 30-30", "description": "Individual adjusted dose of biphasic insulin aspart 30 administered before breakfast and dinner in combination with metformin 500-2000 mg, up to three times daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "210"}, {"groupId": "OG001", "value": "209"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.188", "spread": "0.157"}, {"groupId": "OG001", "value": "0.817", "spread": "0.155"}]}]}]}, {"type": "SECONDARY", "title": "Number of Hypoglycaemic Episodes", "description": "Number of hypoglycaemic episodes occurring after baseline (week 0) to the end of treatment (week 16) in each treatment group. Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 3.1 mmol/L or 56 mg/dL. Symptoms only if subject was able to treat her/himself and with either no plasma glucose or blood glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L or 56 mg/dL.", "populationDescription": "Intention-to-Treat analysis set (ITT) is all randomised subjects exposed to at least one dose of trial product.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "episodes", "timeFrame": "weeks 0-16", "groups": [{"id": "OG000", "title": "BIAsp 50-50-30", "description": "Individual adjusted dose of biphasic insulin aspart 50 administered before breakfast and lunch and individual adjusted dose of biphasic insulin aspart 30 at dinner in combination with metformin 500-2000 mg, up to three times daily"}, {"id": "OG001", "title": "BIAsp 30-30", "description": "Individual adjusted dose of biphasic insulin aspart 30 administered before breakfast and dinner in combination with metformin 500-2000 mg, up to three times daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "219"}, {"groupId": "OG001", "value": "222"}]}], "classes": [{"title": "All", "categories": [{"measurements": [{"groupId": "OG000", "value": "728"}, {"groupId": "OG001", "value": "679"}]}]}, {"title": "Major or Minor", "categories": [{"measurements": [{"groupId": "OG000", "value": "158"}, {"groupId": "OG001", "value": "198"}]}]}, {"title": "Minor", "categories": [{"measurements": [{"groupId": "OG000", "value": "157"}, {"groupId": "OG001", "value": "198"}]}]}, {"title": "Symptoms Only", "categories": [{"measurements": [{"groupId": "OG000", "value": "570"}, {"groupId": "OG001", "value": "481"}]}]}]}, {"type": "SECONDARY", "title": "Number of Nocturnal Hypoglycaemic Episodes", "description": "Number of nocturnal hypoglycaemic episodes occurring after baseline (week 0) to end of treatment (week 16) in each treatment group. Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 3.1 mmol/L or 56 mg/dL. Symptoms only if subject was able to treat her/himself and with either no plasma glucose or blood glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L or 56 mg/dL.", "populationDescription": "Intention-to-Treat analysis set (ITT) is all randomised subjects exposed to at least one dose of trial product.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "episodes", "timeFrame": "weeks 0-16", "groups": [{"id": "OG000", "title": "BIAsp 50-50-30", "description": "Individual adjusted dose of biphasic insulin aspart 50 administered before breakfast and lunch and individual adjusted dose of biphasic insulin aspart 30 at dinner in combination with metformin 500-2000 mg, up to three times daily"}, {"id": "OG001", "title": "BIAsp 30-30", "description": "Individual adjusted dose of biphasic insulin aspart 30 administered before breakfast and dinner in combination with metformin 500-2000 mg, up to three times daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "219"}, {"groupId": "OG001", "value": "222"}]}], "classes": [{"title": "All", "categories": [{"measurements": [{"groupId": "OG000", "value": "134"}, {"groupId": "OG001", "value": "81"}]}]}, {"title": "Major or Minor", "categories": [{"measurements": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "30"}]}]}, {"title": "Minor", "categories": [{"measurements": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "30"}]}]}, {"title": "Symptons Only", "categories": [{"measurements": [{"groupId": "OG000", "value": "103"}, {"groupId": "OG001", "value": "51"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Adverse events were collected over a time span of 16 weeks.", "description": "Safety analysis set is all subjects exposed to at least one dose of trial product.", "eventGroups": [{"id": "EG000", "title": "BIAsp 50-50-30", "description": "Individual adjusted dose of biphasic insulin aspart 50 administered before breakfast and lunch and individual adjusted dose of biphasic insulin aspart 30 at dinner in combination with metformin 500-2000 mg, up to three times daily", "seriousNumAffected": 5, "seriousNumAtRisk": 219, "otherNumAffected": 74, "otherNumAtRisk": 219}, {"id": "EG001", "title": "BIAsp 30-30", "description": "Individual adjusted dose of biphasic insulin aspart 30 administered before breakfast and dinner in combination with metformin 500-2000 mg, up to three times daily", "seriousNumAffected": 9, "seriousNumAtRisk": 222, "otherNumAffected": 68, "otherNumAtRisk": 222}], "seriousEvents": [{"term": "Hypoglycaemic coma", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 222}]}, {"term": "Intestinal obstruction", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 222}]}, {"term": "Cerebral infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 222}]}, {"term": "Spinal osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 222}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 222}]}, {"term": "Intervertebral disc protrusion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 222}]}, {"term": "Breast cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 222}]}, {"term": "Angina unstable", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 222}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 222}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 222}]}, {"term": "Diabetic nephropathy", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 222}]}, {"term": "Clavicle fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 222}]}, {"term": "Leukaemia", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 222}]}], "otherEvents": [{"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 11, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 11, "numAffected": 10, "numAtRisk": 222}]}, {"term": "Hyperlipidaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 15, "numAffected": 15, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 13, "numAffected": 13, "numAtRisk": 222}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 222}]}, {"term": "Myocardial ischaemia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 222}]}, {"term": "Palpitations", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 222}]}, {"term": "Hyperthyroidism", "organSystem": "Endocrine disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 222}]}, {"term": "Conjunctival hyperaemia", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 222}]}, {"term": "Vision blurred", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 222}]}, {"term": "Visual impairment", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 222}]}, {"term": "Abdominal discomfort", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 222}]}, {"term": "Abdominal distension", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 222}]}, {"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 222}]}, {"term": "Colitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 222}]}, {"term": "Intestinal mucosal hypertrophy", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 222}]}, {"term": "Mouth ulceration", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 222}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 222}]}, {"term": "Peptic ulcer", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 222}]}, {"term": "Periodontitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 222}]}, {"term": "Toothache", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 222}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 222}]}, {"term": "Asthenia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 222}]}, {"term": "Chest discomfort", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 222}]}, {"term": "Injection site nodule", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 222}]}, {"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 222}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 222}]}, {"term": "Cholecystitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 222}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 222}]}, {"term": "Hepatic function abnormal", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 222}]}, {"term": "Hepatic pain", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 222}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 222}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 222}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 222}]}, {"term": "Localised infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 222}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 5, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 4, "numAffected": 3, "numAtRisk": 222}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 222}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 6, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 7, "numAffected": 7, "numAtRisk": 222}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 222}]}, {"term": "Joint sprain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 222}]}, {"term": "Lumbar vertebral fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 222}]}, {"term": "Tooth fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 222}]}, {"term": "Vertebral injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 222}]}, {"term": "Alanine aminotransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 222}]}, {"term": "Albumin urine present", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 222}]}, {"term": "Blood triglycerides increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 222}]}, {"term": "Low density lipoprotein increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 222}]}, {"term": "White blood cell count increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 222}]}, {"term": "Anorexia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 222}]}, {"term": "Dyslipidaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 222}]}, {"term": "Hypercholesterolaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 222}]}, {"term": "Hyperkalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 222}]}, {"term": "Hypokalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 222}]}, {"term": "Hyponatraemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 222}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 222}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 222}]}, {"term": "Joint swelling", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 222}]}, {"term": "Musculoskeletal pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 222}]}, {"term": "Neck pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 222}]}, {"term": "Osteoporosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 222}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 3, "numAffected": 2, "numAtRisk": 222}]}, {"term": "Periarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 222}]}, {"term": "Periostitis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 222}]}, {"term": "Cerebral ischaemia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 222}]}, {"term": "Convulsion", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 222}]}, {"term": "Diabetic neuropathy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 222}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 222}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 222}]}, {"term": "Hypoaesthesia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 222}]}, {"term": "Lacunar infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 222}]}, {"term": "Insomnia", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 222}]}, {"term": "Renal failure chronic", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 222}]}, {"term": "Urinary tract disorder", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 222}]}, {"term": "Pruritus genital", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 222}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 222}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 222}]}, {"term": "Neurodermatitis", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 222}]}, {"term": "Photodermatosis", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 222}]}, {"term": "Pruritus", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 222}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 222}]}, {"term": "Subcutaneous nodule", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 222}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 222}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Manuscripts for publication will be prepared in collaboration between Investigator(s) and Novo Nordisk. Novo Nordisk will not suppress or veto publications; however Novo Nordisk reserves the right to postpone publication and/or communication for a short time to protect intellectual property."}, "pointOfContact": {"title": "Public Access to Clinical Trials", "organization": "Novo Nordisk A/S", "email": "clinicaltrials@novonordisk.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Diabetes Mellitus, Type 2", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000007328", "term": "Insulin"}, {"id": "C000557859", "term": "Insulin, Globin Zinc"}, {"id": "D000008687", "term": "Metformin"}, {"id": "D000061267", "term": "Insulin Aspart"}, {"id": "D000049528", "term": "Insulin, Long-Acting"}, {"id": "C000578220", "term": "Insulin degludec, insulin aspart drug combination"}, {"id": "D000061265", "term": "Biphasic Insulins"}, {"id": "C000557564", "term": "Insulin aspart, insulin aspart protamine drug combination 30:70"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M10365", "name": "Insulin", "asFound": "Blood", "relevance": "HIGH"}, {"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M173166", "name": "Insulin, Globin Zinc", "asFound": "Blood", "relevance": "HIGH"}, {"id": "M29801", "name": "Insulin Aspart", "asFound": "Obtained", "relevance": "HIGH"}, {"id": "M29799", "name": "Biphasic Insulins", "asFound": "Institutional", "relevance": "HIGH"}, {"id": "M17768", "name": "Zinc", "relevance": "LOW"}, {"id": "M26073", "name": "Insulin, Long-Acting", "asFound": "Obtained", "relevance": "HIGH"}, {"id": "M117006", "name": "Insulin degludec, insulin aspart drug combination", "asFound": "Obtained", "relevance": "HIGH"}, {"id": "M14342", "name": "Protamines", "relevance": "LOW"}, {"id": "M350709", "name": "Insulin aspart, insulin aspart protamine drug combination 30:70", "asFound": "One side", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Micro", "name": "Micronutrients"}, {"abbrev": "Coag", "name": "Coagulants"}]}}, "hasResults": true}